406 related articles for article (PubMed ID: 30978155)
21. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
22. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.
Højfeldt SG; Wolthers BO; Tulstrup M; Abrahamsson J; Gupta R; Harila-Saari A; Heyman M; Henriksen LT; Jónsson ÒG; Lähteenmäki PM; Lund B; Pruunsild K; Vaitkeviciene G; Schmiegelow K; Albertsen BK;
Br J Haematol; 2019 Feb; 184(3):405-417. PubMed ID: 30450575
[TBL] [Abstract][Full Text] [Related]
23. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
25. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
26. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years.
Rank CU; Toft N; Tuckuviene R; Grell K; Nielsen OJ; Frandsen TL; Marquart HVH; Albertsen BK; Tedgård U; Hallböök H; Ruud E; Jarvis KB; Quist-Paulsen P; Huttunen P; Wartiovaara-Kautto U; Jónsson ÓG; Trakymiene SS; Griškevičius L; Saks K; Punab M; Schmiegelow K
Blood; 2018 May; 131(22):2475-2484. PubMed ID: 29661787
[TBL] [Abstract][Full Text] [Related]
27. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
[TBL] [Abstract][Full Text] [Related]
28. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
[TBL] [Abstract][Full Text] [Related]
29. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
Hasan H; Shaikh OM; Rassekh SR; Howard AF; Goddard K
Pediatr Blood Cancer; 2017 Jan; 64(1):81-88. PubMed ID: 27578304
[TBL] [Abstract][Full Text] [Related]
30. Trypsin-encoding
Wolthers BO; Frandsen TL; Patel CJ; Abaji R; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Grosjean M; Krajinovic M; Larsen E; Liang DC; Möricke A; Rasmussen KK; Samarasinghe S; Silverman LB; van der Sluis IM; Stanulla M; Tulstrup M; Yadav R; Yang W; Zapotocka E; Gupta R; Schmiegelow K;
Haematologica; 2019 Mar; 104(3):556-563. PubMed ID: 30467200
[TBL] [Abstract][Full Text] [Related]
31. Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children With Acute Lymphoblastic Leukemia.
Raja RA; Schmiegelow K; Henriksen BM; Leth Frandsen T
Pediatr Hematol Oncol; 2015; 32(7):474-81. PubMed ID: 26270775
[TBL] [Abstract][Full Text] [Related]
32. Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.
Vyas C; Jain S; Kapoor G; Mehta A; Takkar Chugh P
Pediatr Hematol Oncol; 2018; 35(5-6):331-340. PubMed ID: 30488741
[TBL] [Abstract][Full Text] [Related]
33. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
[TBL] [Abstract][Full Text] [Related]
34. Parents' and Adolescents' Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials.
Tulstrup M; Larsen HB; Castor A; Rossel P; Grell K; Heyman M; Abrahamsson J; Söderhäll S; Åsberg A; Jonsson OG; Vettenranta K; Frandsen TL; Albertsen BK; Schmiegelow K;
Pediatr Blood Cancer; 2016 May; 63(5):865-71. PubMed ID: 26717887
[TBL] [Abstract][Full Text] [Related]
35. Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Buie LW; Moore J; van Deventer H
Pharmacotherapy; 2014 Aug; 34(8):e149-51. PubMed ID: 25112526
[TBL] [Abstract][Full Text] [Related]
36. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration.
August KJ; Miller WP; Dalton A; Shinnick S
J Pediatr Hematol Oncol; 2013 Oct; 35(7):e283-6. PubMed ID: 23619117
[TBL] [Abstract][Full Text] [Related]
37. Prolonged
Mondelaers V; Suciu S; De Moerloose B; Ferster A; Mazingue F; Plat G; Yakouben K; Uyttebroeck A; Lutz P; Costa V; Sirvent N; Plouvier E; Munzer M; Poirée M; Minckes O; Millot F; Plantaz D; Maes P; Hoyoux C; Cavé H; Rohrlich P; Bertrand Y; Benoit Y;
Haematologica; 2017 Oct; 102(10):1727-1738. PubMed ID: 28751566
[TBL] [Abstract][Full Text] [Related]
38. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Gupta S; Wang C; Raetz EA; Schore R; Salzer WL; Larsen EC; Maloney KW; Mattano LA; Carroll WL; Winick NJ; Hunger SP; Loh ML; Devidas M
J Clin Oncol; 2020 Jun; 38(17):1897-1905. PubMed ID: 32275469
[TBL] [Abstract][Full Text] [Related]
39. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
40. Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU.
Lebovic R; Pearce N; Lacey L; Xenakis J; Faircloth CB; Thompson P
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28436558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
